BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8026830)

  • 1. Actin-binding protein expression in benign and malignant melanocytic proliferations.
    Bouffard D; Duncan LM; Howard CA; Mihm MC; Byers HR
    Hum Pathol; 1994 Jul; 25(7):709-14. PubMed ID: 8026830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fascin expression in melanocytic lesions of the skin.
    YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
    Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.
    Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G
    Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMB-45 staining of dysplastic nevi. Support for a spectrum of progression toward melanoma.
    Smoller BR; McNutt NS; Hsu A
    Am J Surg Pathol; 1989 Aug; 13(8):680-4. PubMed ID: 2473661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nevoid malignant melanoma: morphologic patterns and immunohistochemical reactivity.
    McNutt NS; Urmacher C; Hakimian J; Hoss DM; Lugo J
    J Cutan Pathol; 1995 Dec; 22(6):502-17. PubMed ID: 8835170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
    Skender-Kalnenas TM; English DR; Heenan PJ
    J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of cytokine-induced protein gamma-immune protein-10 (gamma-IP10) in atypical melanocytic proliferations.
    Smoller BR; Krueger J
    J Am Acad Dermatol; 1991 Oct; 25(4):627-31. PubMed ID: 1724247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actin-binding protein expression in melanocytic proliferations.
    Cramer SF
    Hum Pathol; 1995 Feb; 26(2):245-6. PubMed ID: 7860058
    [No Abstract]   [Full Text] [Related]  

  • 11. Interleukin (IL)-1 alpha- and -1 beta-, IL-6-, and tumor necrosis factor-alpha-like immunoreactivities in human common and dysplastic nevocellular nevi and malignant melanoma.
    Ahmed AA; Nordlind K; Hedblad M; Lagerholm B; Schultzberg M; Lidén S
    Am J Dermatopathol; 1995 Jun; 17(3):222-9. PubMed ID: 8599429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid leukemia-1 expression in benign and malignant melanocytic lesions.
    Wong RP; Khosravi S; Martinka M; Li G
    Oncol Rep; 2008 Apr; 19(4):933-7. PubMed ID: 18357378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanocytic nevi in histologic association with primary cutaneous melanoma of superficial spreading and nodular types: effect of tumor thickness.
    Sagebiel RW
    J Invest Dermatol; 1993 Mar; 100(3):322S-325S. PubMed ID: 8440914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histological spectrum of acquired nevi. An analysis of the intraepidermal melanocytic proliferation in common and dysplastic nevi.
    Urso C; Bondi R
    Pathol Res Pract; 1994 Jun; 190(6):609-14. PubMed ID: 7984520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nevi, other than dysplastic and Spitz nevi.
    Cochran AJ; Bailly C; Paul E; Dolbeau D
    Semin Diagn Pathol; 1993 Feb; 10(1):3-17. PubMed ID: 8506415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased intraepidermal melanocyte frequency and size in dysplastic melanocytic nevi and cutaneous melanoma. A comparative quantitative study of dysplastic melanocytic nevi, superficial spreading melanoma, nevocellular nevi, and solar lentigines.
    Rhodes AR; Melski JW; Sober AJ; Harrist TJ; Mihm MC; Fitzpatrick TB
    J Invest Dermatol; 1983 May; 80(5):452-9. PubMed ID: 6341476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMB-45 staining of dysplastic melanocytic nevi in melanoma risk groups.
    Ahmed I; Piepkorn M; Goldgar DE; Cannon-Albright LA; Meyer LJ; Skolnick MH; Zone JJ
    J Cutan Pathol; 1991 Aug; 18(4):257-60. PubMed ID: 1939784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of novel monoclonal antibody PNL2 and comparison with other melanocyte differentiation markers.
    Busam KJ; Kucukgöl D; Sato E; Frosina D; Teruya-Feldstein J; Jungbluth AA
    Am J Surg Pathol; 2005 Mar; 29(3):400-6. PubMed ID: 15725810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors.
    King R; Googe PB; Weilbaecher KN; Mihm MC; Fisher DE
    Am J Surg Pathol; 2001 Jan; 25(1):51-7. PubMed ID: 11145251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dysplastic melanocytic nevi: quantitative ultrastructural investigation comparing intraepidermal melanocytes of dysplastic melanocytic nevi, superficial spreading melanoma, nevocellular nevi, and normal skin].
    Seki Y; Fitzpatrick TB; Rhodes AR
    Nihon Hifuka Gakkai Zasshi; 1988 Oct; 98(11):1093-103. PubMed ID: 3225938
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.